Janux Therapeutics, Inc.(JANX)Stock Analysis
AI analysis on 2,800+ stocks →Deep AI analysis on 2,800+ stocks →13F Pro Quality Score
Rank #2,503 of 2,962 stocks
Rankings refresh quarterly once 80% of peers have filed (~45 days after quarter-end). Next update: ~Nov 14, 2026.
Revenue Growth
Profitability
Balance Sheet
Earnings Quality
Free Cash Flow
Institutional Flow
Revenue Scale
Dilution Risk
Unusual Activity in JANX
Events flagged as statistical outliers against JANX's own multi-year baseline — not fixed dollar thresholds.
- Score shock2026-08-06
JANX quality score dropped 18 points (25→7) on a new filing
View source filing →
JANX Stock Analysis & AI Quality Score
Data updated 2026-09-11AI stock analysis and institutional research for Janux Therapeutics, Inc. (JANX), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores JANX at 30.1/100 on a 32-signal composite quality model, placing it at rank #2,503 of 2,962 stocks — the bottom half of the AI-ranked universe. JANX scores in the top quartile across revenue growth (88.7). Areas of concern include profitability (3.6) and revenue scale (3.9), which score below median versus the broader universe. Shareholder dilution risk is elevated at 1.2/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q2 2026), Janux Therapeutics, Inc. reports quarterly revenue of $10.3M, net income of $-22.0M, free cash flow of $12.3M. Top institutional holders of JANX by reported 13-F value include RA CAPITAL MANAGEMENT, L.P., BlackRock, Prosight Management, based on the most recent SEC filings. JANX trades on the Nasdaq exchange and files with the SEC under CIK 1817713. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate JANX daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Janux Therapeutics, Inc. directly from SEC EDGAR. Janux Therapeutics, Inc.'s 13F Pro composite quality score has ranged between 7 and 30 since 2023, currently 30.1 — an improving long-term trajectory across 52 quarterly and live scoring snapshots.
Revenue
Q2 2026
$10.3M
Net Income
Q2 2026
$-22.0M
Free Cash Flow
Q2 2026
$12.3M
ROIC
Q2 2026
-13.7%
Revenue & Net Income
Earnings Per Share
Key Financials Over Time
Export Financial Table · ProRevenue
-5.6% YoYNet Income
-64.7% YoYOperating Income
-59.5% YoYEPS (Diluted)
-43.0% YoYTotal Assets
-5.6% YoYOp. Cash Flow
-87.7% YoYFree Cash Flow
-88.5% YoY| Metric | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|---|
| Revenue | $10.0M -5.6% | $10.6M +31.0% | $8.1M -6.1% | $8.6M +136.8% | $3.6M | $0.00 |
| Net Income | $-113.6M -64.7% | $-69.0M -18.4% | $-58.3M +7.6% | $-63.1M -93.0% | $-32.7M -381.6% | $-6.8M |
| Operating Income | $-157.7M -59.5% | $-98.8M -35.4% | $-73.0M -8.8% | $-67.1M -103.7% | $-32.9M -579.9% | $-4.8M |
| EPS (Diluted) | $-1.83 -43.0% | $-1.28 +3.0% | $-1.32 +13.2% | $-1.52 -40.1% | $-1.09 | — |
| Total Assets | $1.00B -5.6% | $1.06B +179.0% | $380.4M +4.5% | $364.0M -4.2% | $379.8M +2242.1% | $16.2M |
| Operating Cash Flow | $-82.2M -87.7% | $-43.8M +13.4% | $-50.6M -17.8% | $-42.9M -152.8% | $-17.0M -288.6% | $-4.4M |
| Free Cash Flow | $-83.3M -88.5% | $-44.2M +15.7% | $-52.4M -6.2% | $-49.4M -167.5% | $-18.5M -322.5% | $-4.4M |
Get alerted when JANX's score changes
Free account: watchlist tracking, the daily AI brief, and the AI screener.
Available Research
13F Pro tracks comprehensive data for Janux Therapeutics, Inc. including:
Top Institutional Holders of JANX
RA CAPITAL MANAGEMENT, L.P.
$171.9M11,189,693 shBlackRock, Inc.
$94.2M6,134,667 shProsight Management, LP
$58.4M3,804,481 shSTATE STREET CORP
$46.2M3,004,899 shFMR LLC
$37.1M2,412,825 shFEDERATED HERMES, INC.
$36.1M2,352,927 shPoint72 Asset Management, L.P.
$30.6M1,993,837 shVANGUARD CAPITAL MANAGEMENT LLC
$28.5M1,857,351 shTCG Crossover Management, LLC
$27.5M1,789,617 shAlyeska Investment Group, L.P.
$25.3M1,647,140 sh
| Fund | Value | Shares |
|---|---|---|
| RA CAPITAL MANAGEMENT, L.P. | $171.9M | 11,189,693 |
| BlackRock, Inc. | $94.2M | 6,134,667 |
| Prosight Management, LP | $58.4M | 3,804,481 |
| STATE STREET CORP | $46.2M | 3,004,899 |
| FMR LLC | $37.1M | 2,412,825 |
| FEDERATED HERMES, INC. | $36.1M | 2,352,927 |
| Point72 Asset Management, L.P. | $30.6M | 1,993,837 |
| VANGUARD CAPITAL MANAGEMENT LLC | $28.5M | 1,857,351 |
| TCG Crossover Management, LLC | $27.5M | 1,789,617 |
| Alyeska Investment Group, L.P. | $25.3M | 1,647,140 |
Companies Similar to JANX
Ranked by quality-profile closeness and shared hedge-fund ownership — not just sector membership.
LENZ Therapeutics, Inc.
Kura Oncology, Inc.
BICYCLE THERAPEUTICS PLC
CG Oncology, Inc.
Instil Bio, Inc.
AGIOS PHARMACEUTICALS, INC.
Crinetics Pharmaceuticals, Inc.
Tango Therapeutics, Inc.
Similarity is computed from the 8 composite sub-scores and latest-quarter 13F conviction holdings (index-style filers excluded). Refreshed monthly.
More Healthcare Companies
View all Healthcare →Put JANX on your watchlist
Track score changes the day Janux Therapeutics, Inc. files with the SEC, follow the hedge funds that own it, screen 2,800+ AI-scored stocks, and get the daily brief — free.
Free tier includes 13F data, economic indicators, and market overview. Pro starts at $6.67/mo (billed annually).
Popular Research
Is JANX a good stock to buy?
13F Pro's AI-powered analysis of Janux Therapeutics, Inc. (JANX) draws on SEC EDGAR-sourced fundamentals, institutional 13F holdings, and insider Form 4 transactions in the Healthcare sector (listed on Nasdaq). The 32-signal AI Quality Score, current rank, and full bull/bear verdict for JANX are available on the JANX stock profile dashboard — with the same data, AI insights, ratios, and institutional activity refreshed after every 10-K, 10-Q, 13F, and Form 4 filing. JANX is classified as a small company.
Which hedge funds own JANX?
Institutional investors are required to disclose their holdings quarterly via SEC Form 13F. 13F Pro aggregates these filings to show which hedge funds, mutual funds, and asset managers are buying or selling JANX. Combined with insider transaction data from Form 4 filings and AI-powered analysis from 10 specialized research agents, 13F Pro provides a comprehensive view of Janux Therapeutics, Inc.'s investment landscape.